This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Angiotensin II receptor inhibitors in hypertension

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • the principal mechanism in which angiotensin II receptor inhibitors lower blood pressure is probably inhibition of angiotensin-mediated vasoconstriction

  • the antihypertensive efficacy of angiotensin II receptor inhibitors appears to be equal to that of atenolol or ACE inhibitors

  • angiotensin II receptor inhibitors and thiazide diuretics may be combined, resulting in additive hypotensive effects; an additive effect also occurs if angiotensin II receptor inhibitors are used with beta blockers

  • the combination of an ACE inhibitor and an angiotensin II receptor antagonist is not recommended (1)

  • angiotensin II receptor inhibitors have a gradual onset of action and adverse effects such as first dose hypotension are rare

  • the ACD strategy for hypertension management suggests an ACE inhibitor (or angiotensin II inhibitor) as first-line therapy for younger (non-black) patients

  • the VALUE trial compared the use of valsartan to amlodipine in the management of hypertension (see linked item)

Reference:

  1. Prescribers' Journal (1999);39 (1): 24-30.
  2. J Hum Hypertens. 2003 Feb;17(2):81-6.

Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.